Rosetta sets strategic alliance

Pico caps Rosetta Genomics (ROSG) and Marina Biotech (MRNA) establish a strategic collaboration to identify and develop microRNA-based products targeting neuromuscular diseases and dystrophies.

Initial focus will be Becker and Duchenne muscular dystrophies and myotonic dystrophy.

Rosetta will identify microRNAs associated with the diseases and, if correlative, will develop the diagnostic products. Marina will develop the therapeutics.

From other sites
Comments (1)
  • Jérôme Verony
    , contributor
    Comments (168) | Send Message
    financial terms of this new 'alliance' unfortunately not disclosed. Why?
    2 Apr 2014, 02:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs